Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
about
UK guidelines for the management of bone sarcomasBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.Treatment pathway of bone sarcoma in children, adolescents, and young adultsTargeted Therapy of Ewing's Sarcoma.Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directionsPrognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.Primary Multiple Pulmonary Primitive Neuroectodermal Tumor: Case Report and Literature Review.Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective studyBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q26752425-94EABDA0-98CF-417E-8F7F-26AED66C7E16Q33274572-F95C6939-216D-41E9-A0D6-43560BEBC07BQ33417823-21BB88F0-3A77-430A-A284-36E2ECE58927Q33835657-100C53D5-C293-46E0-8C9C-8D36E1B381C5Q34262377-3B61B9D3-716F-4B61-92B9-A02C654D01A9Q34787772-0659F617-C69E-459B-AC0E-EC6C48DFE786Q35607070-57D308AB-C422-4F35-953A-7F9604C0889DQ35624209-02083F54-7791-4E6E-9464-1AF4448E4BB7Q35957998-E7D8DE8E-CF35-49DA-8987-79FA1D2D5B1DQ37688646-0895CA21-99C6-4A56-8D01-D165C5E4CC7EQ38545666-9EF99216-0EAD-4147-839B-792BB3EB97C8Q44611540-D443BC7D-58B1-436C-BC88-080A11942A0BQ45969231-D8C0C9DC-6123-45BB-A035-BBDBF530CC15Q46090646-7E6FC0CE-4E1A-41DA-8522-6C5C4D97F4A4Q47355674-F0317C97-30AF-434B-BEE7-DF5BA2CFBCAEQ57570538-48F6095A-99C0-4987-BCC9-A52C2EF66B39Q57570627-9E66E18A-D092-46E0-8D93-C001583851AD
P2860
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@ast
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@en
type
label
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@ast
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@en
prefLabel
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@ast
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@en
P2093
P356
P1476
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
@en
P2093
A Balladelli
A Brach del Prever
P304
P356
10.1002/PBC.21917
P577
2009-05-01T00:00:00Z